WHO comparative evaluation of serologic assays for Chagas disease


Autoria(s): OTANI, Marcia M.; VINELLI, Elizabeth; KIRCHHOFF, Louis V.; POZO, Ana del; SANDS, Anita; VERCAUTEREN, Gaby; SABINO, Ester C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Evaluation of commercially available test kits for Chagas disease for use in blood bank screening is difficult due to a lack of large and well-characterized specimen panels. This study presents a collaborative effort of Latin American blood centers and the World Health Organization (WHO) to establish such a panel. A total of 437 specimens, from 10 countries were collected and sent to the WHO Collaborating Center in Sao Paulo and used to evaluate 19 screening assays during 2001 through 2005. Specimens were assigned a positive or negative status based on concordant results in at least three of the four confirmatory assays (indirect immunofluorescence, Western blot, radioimmunoprecipitation assay, and recombinant immunoblot). Of the 437 specimens, 168 (39%) were characterized as positive, 262 (61%) were characterized as negative, and 7 (2%) were judged inconclusive and excluded from the analysis. Sensitivity and specificity varied considerably: 88 to 100 and 60 to 100 percent, respectively. Overall, enzyme immunoassays (EIAs) performed better than the other screening assays. Four EIAs had both parameters higher than 99 percent. Of the four confirmatory assays, only the RIPA gave a 100 percent agreement with the final serologic status of the specimens. The sensitivities and specificities of at least four of the commercially available EIAs for Chagas disease are probably high enough to justify their use for single-assay screening of blood donations. Our data suggest that the majority of commercially available indirect hemagglutination assays should not be used for blood donor screening and that the RIPA could be considered a gold standard for evaluating the performance of other assays.

Mauricio Beltran Duran (Instituto Nacional de Salud, Colombia)

Marco Antonio Heroiza Holgin (Secretario Nacional de Bancos de Sangre, Ecuador)

Graciela Velasquez (Universidad Nacional de Asuncion, Instituto de Investigaciones en Ciencias de la Salud, Paraguay)

Elizabeth Vinelli (Cruz Roja Hondurena, Honduras)

Ana del Pozo (Hospital de Pediatria ""Prof. Dr Juan P. Garrahan,"" Argentina)

Maria del Carmen Zambraba M. (Banco de Sangre Regional de Cochabamba, Bolivia)

Antonio Marin y Lopez (Centro Nacional de Transfusion Sanguinea, Mexico)

Graciela Echegoyen de Hernandez (Cruz Roja Salvadorena, El Salvador)

RenE Berrios Cruz (Cruz Roja Nicaraguense, Nicaragua)

Identificador

TRANSFUSION, v.49, n.6, p.1076-1082, 2009

0041-1132

http://producao.usp.br/handle/BDPI/19866

10.1111/j.1537-2995.2009.02107.x

http://dx.doi.org/10.1111/j.1537-2995.2009.02107.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL PUBLISHING, INC

Relação

Transfusion

Direitos

restrictedAccess

Copyright WILEY-BLACKWELL PUBLISHING, INC

Palavras-Chave #TRYPANOSOMA-CRUZI INFECTION #BENZNIDAZOLE #SERODIAGNOSIS #ANTIGENS #EFFICACY #ANTIBODY #TRIAL #Hematology
Tipo

article

original article

publishedVersion